Table II.
Characteristics of atrial fibrillation patients with and without stroke incidence during 3-year follow-up
| Variable | Stroke | P-value | |
|---|---|---|---|
| Absent (N = 98, 89.1%) | Present (N = 12, 10.9%) | ||
| Diabetes, n (%) | 3 (3.1) | 3 (25.0) | 0.017 |
| Heart failure, n (%) | 14 (14.3) | 6 (50.0) | 0.008 |
| ACEI, n (%) | 25 (25.5) | 9 (75.0) | 0.001 |
| Fibrinogen [g/l] | 4.00 (2.38; 4.83) | 4.38 (3.91; 5.16) | 0.04 |
| VWF (%) | 201.5 (168.0; 236.8) | 238.5 (210.8; 278.0) | 0.006 |
| D-dimer [ng/ml] | 215.0 (154.8; 277.5) | 317.0 (287.5; 404.0) | 0.0001 |
| TF present, n (%) | 10 (10.2) | 6 (50.0) | 0.002 |
| FXIa present, n (%) | 11 (11.2) | 5 (41.7) | 0.015 |
| FIXa present, n (%) | 22 (22.7) | 6 (50.0) | 0.073 |
| FIXa, FXIa or TF present, n (%) | 37 (37.8) | 12 (100) | < 0.0001 |
| Time in therapeutic range (%) | 75.0 (65.0; 85.0) | 55.0 (45.0; 60.0) | < 0.0001 |
| CHADS2 1 point, n (%) | 47 (48.0) | 0 (0.0) | 0.0011 |
| CHADS2 ≥ 2 points, n (%) | 18 (18.4) | 9 (75.0) | 0.0001 |
Abbreviations see Table I. ACEI – angiotensin-converting enzyme inhibitor.